J9329 Injection, tislelizumab-jsgr
J-Codes
Also known as: tislelizumab, Beyfortus
Injection of tislelizumab-jsgr, a programmed cell death ligand 1 (PD-L1) monoclonal antibody. Immune checkpoint inhibitor.
Clinical Context
Used for non-small cell lung cancer and other malignancies expressing PD-L1. Checkpoint inhibitor with reduced immunotoxicity profile.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.